Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
This publication addresses the critical need for standardized genomic testing guidelines in metastatic breast cancer (MBC) within China, where breast cancer remains highly prevalent.
It highlights the challenges posed by the spatiotemporal heterogeneity and dynamic evolution of MBC genomes, emphasizing the importance of precision medicine through targeted therapies guided by genomic profiling.
Recognizing the absence of detailed national technical specifications and clinical pathways tailored to China’s healthcare context, a multidisciplinary expert group developed a guideline that integrates the latest evidence and expert consensus.
The guideline provides clear recommendations on:
- Patient selection
- Specimen handling
- Testing methods
- Priority genes for MBC genomic testing
Additionally, it aligns targeted therapeutic options with evidence levels and drug availability specific to China.
The aim is to enhance clinical operability, unify testing standards, optimize workflows, and ultimately improve patient outcomes by facilitating access to precision treatments in advanced breast cancer care.